45 results
8-K
EX-99.1
SPRY
ARS Pharmaceuticals Inc
7 Mar 24
Results of Operations and Financial Condition
12:56pm
for efficacy observed even 1 minute after dosing No irritation based on formal assessment PK bracketed by approved products (exposures ≥ IM/SC … the various approved injection devices despite different PK
Risk-benefit assessment of neffy Thomas B. Casale, M.D. Professor of Medicine & Pediatrics
8-K
EX-99.1
SPRY
ARS Pharmaceuticals Inc
25 Sep 23
Regulation FD Disclosure
4:17pm
current epinephrine injectables market FDA AdCom supports favorable benefit-risk assessment, but FDA requested one additional study (twice-dosing nasal … based on formal assessment No serious adverse events in any clinical study No risk of needle-related injuries or blood vessel injections with neffy PD
8-K
EX-99.1
s1dcge6n8ozn6yd2av3m
16 May 23
Regulation FD Disclosure
4:31pm
8-K
EX-99.1
wbkvqb
15 May 23
ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results
9:03am
8-K
EX-99.1
w3x7ezm7rp4hwo2eu
9 May 23
Regulation FD Disclosure
9:12am
8-K
EX-99.1
dcv966qb9typ6p
6 Dec 22
Regulation FD Disclosure
5:07pm
8-K
EX-2.1
7tfv1n
8 Nov 22
ARS Pharmaceuticals Closes Merger with Silverback Therapeutics
4:51pm
DEFA14A
6cb cl8cbts
27 Oct 22
Additional proxy soliciting materials
4:15pm
DEFM14A
b63hfxzjlm8tt
6 Oct 22
Proxy related to merger
4:16pm
PRER14A
mqq4pw j6gdotggl
16 Sep 22
Preliminary revised proxy
4:56pm
CORRESP
h1vjr 1lw5
16 Sep 22
Correspondence with SEC
12:00am
UPLOAD
vjyfo mjofx27abb
9 Sep 22
Letter from SEC
12:00am
PREM14A
jwqaakke
11 Aug 22
Preliminary proxy related to merger
5:22pm